Scott Alfred Fretzin, MD
Dawes Fretzin Clinical Research Group, LLC
Indiana University School of Medicine (Indianapolis, IN)Dermatology Residency, 1997
University of Chicago Pritzker School of Medicine (Chicago, IL)Internal Medicine Internship, 1994
University of Chicago Pritzker School of Medicine (Chicago, IL)Medical Doctorate, 1993
Washington University (St. Louis, MO)Bachelor of Arts in Philosophy, 1989
Professional Experience Dawes Fretzin Clinical Research Group, LLC (Indianapolis, IN) Investigator, 2004-Present Dawes Fretzin Dermatology Group, LLC (Indianapolis, IN) Dermatologist, 1999-Present BellFlower County Clinic (Indianapolis, IN) Dermatologist (part-time), 1997-Present Indiana University School of Medicine (Indianapolis, IN) Volunteer Assistant Professor Clinical Dermatology, May 2011- Present Indiana University School of Medicine (Indianapolis, IN) Clinical Assistant Professor, 1997- May 2011 Dawes Dermatology Group (Indianapolis, IN) Dermatologist, 1997-99 Honors and Awards
Honorable Mention, Young Investigators Competition, Dermatol Surg
Genetics Society of America Summer Research Fellowship
1987-88 Scholarship and Leadership Award, Kappa Sigma National Fraternity
Scott Alfred Fretzin, MD Clinical Study Experience (Other than Dawes Fretzin Clinical Research Group, LLC) Genital Warts Sponsor: 3M Safety and efficacy trial evaluation 5% Imiquimod Cream application to external genital
warts and an extended treatment area; 1999-02Diabetes Sponsor: Takeda Acting Agent: Quintiles, Inc. An open-label, long-term extension study of voglibose (AO_128) in Type II Diabetes
Mellitus patients; March 1997 to June 1999Atopic Dermatitis Sponsor: Connetics Therapeutics An open-label, follow-on study of the safety and efficacy of Recombinant Interferon-y 1b
in subjects with moderate to severe atopic Dermatitis; September 1996 to December1998Atopic Dermatitis Sponsor: Connetics Therapeutics A Phase III study of the safety and efficacy of Recombinant Interferon-y 1b in subjects
with moderate to severe atopic Dermatitis; September 1996 to April 1998Diabetes Sponsor: Takeda Acting Agent: Covance, Inc A double-Blind, Placebo-Controlled, Randomized, Dose-Titration Study to Evaluate the
Safety and Efficacy of Pioglitazone; January 1997 to December 1998Scalp Psoriasis Sponsor: Connetics Therapeutics A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Betamethasone
Valerate Foam in Treating Scalp Psoriasis; April 1997 to December 1997Bronchitis Sponsor: Bristol-Myers Squibb A Double-blind Multicenter Compartive Study of Cefprozil (250mg bid) versus
Cefuroxime Axetil (250mg bid) in the Treatment of Bronchitis; December 1995 toApril 1997Non-Insulin Dependent Diabetes Mellitus Sponsor: Parke Davis A 20-week, Double-Blind, Randomized Study of Troglitazone (CL-991) in patients with
Non-Insulin Dependent Diabetes Mellitus; June 1995 to May 1997Diabetes Sponsor: Takeda Acting Agent: Quintiles, Inc A Randomized, Double-Blind, Placebo-Controlled, Six-Month, Safety and Efficacy Trial
of 0.1, 0.5, 1, 2, 5 mg TID of Voglibose (AO-128) in Type II Diabetes MellitusPatients; October 1996 to December 1997Scott Alfred Fretzin, MD Clinical Study Experience (Cont) Osteoarthritis Sponsor: Merck A Double-Blind, Randomized, Multicenter Study to Compare the Safety of Dexibuprofen
Lysine with Ibuprofen for Long-Term Treatment of Osteoarthritis; September 1996 toRheumatoid Arthritis Sponsor: Boston Life Sciences, Inc A Double-Blind, Randomized Study of Therafectin 6 grams/day compared to Placebo in
Patients with Rheumatoid Arthritis Withdrawn from their Nonsteroidal Anti-Inflammatory Drug Therapy; June 1996 to July 1997Psoriasis Sponsor: Sergen, Inc Phase II Randomized, Double-Blind, Placebo-Controlled Trial of DAB389IL-2 in Patients
with Moderate to Severe Plaque-Type Psoriasis; June 1995 to October 1996Xerostomia and Keratoconjunctivitis Sicca Sponsor: Snowbrand Milk Products, Acting Agent: Pharmaco LSR A pilot study of SNI-2011 in patients with Sjogren's Syndrome experiencing xerostomia
and keratoconjunctivitis Sicca; July 1995 to December 1996Intermittent Claudication Sponsor: Marion Merrell Dow Dose-Response Evaluation of Beraprost Sodium IR Tablets in Treatment of Intermittent
Claudication; October 1995 to December 1996Articles and Publications
Krueger JG, Fretzin S, Suárez-Fariñas M, Haslett PA, Phipps KM, Cameron GS,
McColm J, Katcherian A, Cueto I, White T, Banerjee S, Hoffman RW. “IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis.” J Allergy Clin Immunol. 2012 Jul;130(1):145-154.e9. Epub 2012 Jun 5.
Gottlieb, A., Menter, A., Mendelsohn, A., Yaung-Kaung, S., Guzzo, C., Fretzin, S.,
Kunynetz, R., Kavanaugh, A. “Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial.” Lancet, 2009 Feb 21; 373:633.
Papp, K., Bressinck, R., Fretzin, S., Goffe, B., Kempers, S., Gordon, K., Caro, I.,
Walicke, P., Wang, X., Mentor, A. “Safety of efalizumab in adults with chronic Moderate to severe plaque psoriasis: A phase IIIb, randomized, controlled trial.” International Journal of Dermatology, May 2006; Vol 45, Number 5: 605-614.
Crowley, J., Fretzin, S., Sobell, J. “New Treatment Options for Psoriasis Involving the Hands and Feet.” Biologic Bulletin, March 2006.
Fretzin, S. “Recent Advances in the Treatment of Psoriasis with Efalizumab Therapy.” US Dermatology Review, 2006 Issue II: 12-14.
Fretzin, S. “Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis Involving the Hands and Feet with Raptiva®” DermPA Today, Spring 2006; Vol 3, Number 1:4-5.
Fretzin, S. “Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis Involving the Hands and Feet with Raptiva®” DermNurse, Spring 2006; Vol 2, Number 1:3-4. Scott Alfred Fretzin, MD Articles and Publications (Cont)
Fretzin, S. “Managing Cases of Chronic, Moderate-to-Severe Plaque Psoriasis Involving the Hands and Feet with Raptiva®” Derm Resident, Spring 2006; Vol 5, Number 5:5-6.
Fretzin S., Crowley, J., Jones, L., Young, M., Sobell, J. “Successful Treatment of Hand And Foot Psoriasis with Efalizumab Therapy.” Journal of Drugs in Dermatology. October 2006; Vol 5, Issue 9; 838-846.
Fretzin S., Dawes K. J Am Acad Dermatol 2005; 52:P182. Abstract P2745. S. Fretzin. “Answer All Your Patients’ Questions About STDs.” Skin Aging 2000; 8
R. Huff, S. Fretzin, C. Lewis. “Penile Eruption on a Diabetic Man.” Arch Dermatol
R Huff, S. Fretzin. “Vesicular Eruption on the Chest and Back.” Archives of
S. Fretzin. “Ringworm and Molluscum Contagiosum.” Indiana Amateur Wrestling
M. Fretzin, S. Fretzin, D. Fretzin. “A Papulonecrotic Eruption in a Young Man.” Arch
T. Eads, S. Fretzin, C. Lewis. “Pruritic, Painful Eruption.” Arch Dermatol 1998;
S. Fretzin. “Introduction to the Terminology of Ethics.” Ethics Workbook for
Dermatology Residency Directors. 1998.
S. Fretzin, W. Beeson, W. Hanke. “Ignition Potential of the 585 nm Pulsed Dye Laser: Review of the Literature and Safety Recommendations.” Dermatol Surg 1996; 22 699-702.
G. Westhoven, S. Fretzin, C. Lewis. “A Woman with Lung Cancer and Exfoliative Dermatitis.” Arch Dermatol 1997; 133: 499-504.
D. Fretzin, J. Sloan, K. Beer, S. Fretzin. “Eccrine Syringofibroadenoma: A Clear Cell Variant.” Am.J. of Dermatopathology 1995;17 (6): 591-593
S. Fretzin, B. Allen, A. Vane Daal, S. Elgin. “A Drosophila melanogaster H3.3 cDNA Encodes a Histone Variant Identical with the Vertebrate H3.3.” Gene. 107 (1991) 341-342.
F. Booyse, R. Bruce, M. Grover, S. Fretzin, J. Karkov, H. Modi, L. Casey. “Rapid Release of Plasminogen Activators From Cultured Human Umbilical Vein Endothelial Cells.” Blood. 66#5 (1985). Presentations/Posters
World Congress of Dermatology. C. Leonardi, J. Sobell, S. Fretzin, H. Sofen, T. Hamilton, Y. Chen, C, Ivor, A. Menter. Phase IV Study to Evaluate the Safety andEfficacy of Efalizumab in the Treatment of Hand and Foot Plaque Psoriasis. October,2007
68th SID Annual Meeting. A. Ehrlich, S. Fretzin, W. Werther, Y. Chen, I. Caro, D. Pariser. Prevalence of Cardiovascular Risk Factors by Psoriasis Severity in Biologic-Treated Patients: The RESPONSE Cohorts. May 9-12, 2007.
Australasian College of Dermatologists 39th Annual Scientific Meeting. S. Fretzin,K. Dawes, AC Rundle, I Caro. Safety of a topically applied novel small moleculeinhibitor of the Hedgehog signaling pathway in subjects with basal cell carcinoma. May14-17, 2006. Scott Alfred Fretzin, MD Presentations/Posters (Cont)
The American Academy of Dermatology Meeting (64th Annual). J. Sobell, S. Fretzin. Case studies of efalizumab in hand and foot psoriasis. March 3-7, 2006.
The American Academy of Dermatology Meeting. S. Fretzin, A. Menter, R. Langley,D. Cohen. Therapeutic Strategies and Treatments for Psoriasis (CME/CD-ROM). February, 2005.
The American Academy of Dermatology Meeting. S. Fretzin, K. Dawes. Efficacy andSafety of Efalizumab for Patients with Palmoplantar Pustulosis. February, 2005.
The American Academy of Dermatology Meeting. S. Fretzin, J. Cotton, A. Hood. Aleukemic Lymphoblastic Leukemia Cutis in a 14 month-old girl. San Francisco,California. 1997.
The American Society for Dermatopathology Meeting. J. Cotton, S. Fretzin, A. Hood. Cutaneous Lymphoblastic Lymphoma in children. Two case reports and review of theliterature. San Francisco, California. March, 1997.
The United States and Canadian Academy of Pathology Meeting. J. Cotton, S. Fretzin,R. Neiman. Cutaneous Lymphoblastic Lymphoma in children. Two case reports andreview of the literature. Orlando, Florida. March 1997.
St. Vincent’s Hospital Dermatopathology Conference. S. Fretzin. Degos’ Syndrome. January 1997.
St. Vincent’s Hospital Dermatopathology Conference. S. Fretzin. Well’s Syndrome. September 1996.
The American Academy of Dermatopathology Meeting, 1996. S. Fretzin, H. Faust. Atypical Cutaneous reaction to Benazepril with histologic features of Mycosis Fungoides.
The American Society for Cell Biology Regional Meeting. Poster Presentation. S. Elgin,A. Van daal, S. Fretzin, E. White, M. Gorovsky. “Histone Variants H2Avd and H3.3 ofDrosophila melangaster.” March, 1990.
UCLA Symposium on Transcriptional Control of Cell Growth. A. Van daal, S. Fretzin, E. White, M. Gorovsky, S. Elgin. “Histone Variants H1Avd and H3.3. of Drosophilamelanogaster.” January, 1990. Other Research Experience
Washington University of St. Louis, Dept. of Biology, Sarah C. Elgin,
Ph.D.;Characterization of Drosophila melanogaster Histone Variant Gene.
Barnes Hospital, Dept. of Dermatology, Eugene Bauer, M.D.; Collagenase
assays for research in Epidermolxsis Bullosa.
Michael Reese Hospital, Dept. of Immunology, Enrique Beckman M.D.; GeneRearrangement of Lymphomas.
Michael Reese Hospital, Dept. of Immunology, Francoise Booyse, Ph.D.;
Release of Plasminogen activators from human endothelial cells. Scott Alfred Fretzin, MD License/Certifications
Board Certified in Dermatology, 1997Indiana State License #01044060ACLS CertifiedCITI Certification, February 2012
American Academy of DermatologyIndiana Dermatologic SocietyAmerican Medical Association
Ekloef and Schmidt Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine2012, 20(Suppl 2):P10http://www.sjtrem.com/content/20/S2/P10Community-acquired pneumonia: a comparisonof clinical treatment failure in patients treatedwith either penicillin or cefuroximeJosefin Ekloef*, Thomas A SchmidtFrom 4th Danish Emergency Medicine ConferenceRoskilde, Denmark. 25-26 November 2011cefurox
Acne is a skin condition seen as blackheads, whiteheads, pustules and inflamed and infected nodules found on theface, neck, chest and back. People with Acne often feel self-conscious about the blemishes on their This condition is found more in younger people. In some studies it has been found that as many as 80% teenagers are affected by Acne which can be caused by many factors. Acne can be